Sofya Tishina watched as tiny clusters of human pancreatic cancer cells, grown in a lab dish from patient tissue, began to wither and die—each shrinking sphere a quiet victory in a disease long defined by defeat. At the University of Cologne’s Center for Molecular Medicine, Tishina and her team, led by Professor Dr. Silvia von Karstedt, have uncovered a hidden vulnerability in the most common form of pancreatic cancer—one that could shift the trajectory of a disease with a five-year survival rate still below 12%. Their discovery centers on KRAS-mutant tumors, which drive about 90% of pancreatic ductal adenocarcinoma (PDAC) cases, the deadliest variant. These cancer cells, it turns out, are primed for a fiery form of cell death called necroptosis, but only if their last line of defense—caspase-8—is disabled.
For decades, KRAS mutations have been considered “undruggable,” evading targeted therapies and leaving patients with few options beyond surgery and chemotherapy, neither of which reliably improve long-term outcomes. But the Cologne team found that these very mutations, which hijack cell signaling to fuel uncontrolled growth, also trigger a chronic type I interferon response—a hallmark of innate immune activation. This constant internal alarm doesn’t kill the cancer; instead, it paradoxically prepares the cells for necroptosis, an inflammatory death that ruptures the cell and alerts the immune system. The cancer survives only by relying on caspase-8 to block this process. Remove that brake, and the tumor cells self-destruct.
In genetically engineered mouse models, depleting caspase-8 led to a dramatic reduction in precancerous lesions—some shrinking by more than half. When researchers combined existing clinical drugs to pharmacologically induce necroptosis, tumor growth slowed and survival times increased. Even more encouraging: the same results held in human-derived organoids, three-dimensional mini-tumors grown directly from patient biopsies. These complex models, which mimic the biology of real tumors more closely than traditional cell lines, responded robustly to the treatment, suggesting the approach could translate to people.
“This is more than a lab curiosity,” says Tishina, the study’s first author. “We’re seeing consistent cell death across multiple models, including human tissue, which gives us real hope for future therapies.” The team’s collaboration with the German Consortium for Translational Cancer Research (DKTK), the Technical University of Munich, and international partners underscores the work’s clinical ambition. While human trials are still ahead, the fact that the drugs used in combination are already approved for other conditions could accelerate the path to testing in patients.
Pancreatic cancer is on track to become a leading cause of cancer death worldwide. But in a quiet lab in Cologne, a new strategy is taking shape—one that turns the cancer’s greatest strength into its fatal flaw.